Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning
Alireza Rezvani(Shiraz University of Medical Sciences), Robert Lowsky(Stanford University), Judith A. Shizuru(Stanford University), Jonathan Benjamin(Amgen (United States)), Linda J. Johnston(Université Bourgogne Franche-Comté), Saurabh Chhabra(Medical College of Wisconsin), Sally Arai(Stanford Medicine), Abraham S. Kanate(HonorHealth), Ginna G. Laport(Stanford Blood Center), David B. Miklos(Stanford University), Holbrook E. Kohrt(Stanford University), B. Efron(Stanford University), W-K Weng(Stanford University), S Strober(Stanford Blood Center), Robert S. Negrin(Stanford University)
Cited by 9
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k